XIDE » Topics » Stock Options

This excerpt taken from the XIDE DEF 14A filed Jul 27, 2006.
Stock Options
 
Stock options granted under the 2004 Plan may be either non-qualified stock options or incentive stock options qualifying under Section 422 of the Internal Revenue Code of 1986, as amended. Incentive stock options may be granted only to employees of our company and its affiliates. Stock options granted under the 2004 Plan will vest on the schedule determined by the Committee. The Committee may accelerate the vesting of stock options under certain circumstances. Most of the awards which have been granted under the 2004 Plan to date have a three-year vesting schedule, all of which are subject to shareholder approval. To the extent that the aggregate fair market value of shares of common stock underlying incentive stock options exceeds $100,000 when those options first become exercisable by a participant in any calendar year, the options in excess of $100,000 will be treated as non-qualified stock options.
 
The exercise price of any stock option granted under the 2004 Plan may not be less than the fair market value of our common stock on the date the option is granted. However, with respect to incentive stock options granted to employees who own stock representing more than 10% of the combined voting power of all classes of stock of our company or any affiliate, the exercise price may not be less than 110% of the fair market value of our common stock on the date the option is granted. The Committee may allow the exercise price to be paid in cash or check, with other shares of our common stock or through a cashless exercise program using a broker-dealer.


15


Table of Contents

The Committee will determine the term of each stock option granted under the 2004 Plan. The Committee has discretion to provide for a term of up to ten years. However, for incentive stock options granted to employees who own stock representing more than 10% of the combined voting power of all classes of stock of our company or any affiliate, the term of the option may not exceed five years.
 
To the extent the award agreement governing a grant does not specify the terms and conditions upon which a stock option will terminate in the event of the termination of a participant: (1) if a termination results from “disability” within the meaning of Section 22(e)(3) of the Internal Revenue Code of 1986, as amended, the participant may exercise the option at any time within one year following the termination, to the extent the participant was entitled to exercise the option at the date of termination; (2) if a termination results from the participant’s death, or if death of the participant occurs within thirty days following the termination, the participant’s estate or person with rights to exercise the option may exercise the option at any time within one year following the date of the participant’s death, to the extent the option had vested at the date of the participant’s death or termination, as applicable; (3) if the participant is terminated for cause, the right to exercise the option is immediately forfeited and considered null and void; and (4) if a termination occurs for any other reason, the participant may exercise the option at any time within 90 days following the termination, to the extent the participant was entitled to exercise the option at the date of termination.
 
No stock option granted under the 2004 Plan may be re-priced or surrendered in exchange for a replacement option having a lower exercise price except in connection with a stock split, stock dividend or similar event in order to prevent dilution or enlargement of benefits intended to be made available under the 2004 Plan.
 
This excerpt taken from the XIDE 10-K filed Jun 29, 2005.

Stock Options

 

As provided for in SFAS No. 123, “Accounting for Stock-Based Compensation” (“SFAS 123”) the Company utilizes the intrinsic value method of expense recognition under APB Opinion No. 25. Accordingly, no compensation cost has been recognized for the stock option plans as the fair market value at date of grant was less than or equal to the exercise price. Had compensation expense for the stock option plans been determined consistently with the provisions of SFAS 123, the Company’s net income (loss) and net income (loss) per share would have been the pro forma amounts indicated below:

 

     Successor
Company


    Predecessor Company

 
    

Period from

May 6, 2004 to

March 31, 2005


   

Period from

April 1, 2004 to

May 5, 2004


    Fiscal Year Ended March 31,

 
               2004      

          2003      

 

Net income (loss) as reported:

   $ (466,923 )   $ 1,748,564     $ (114,083 )   $ (140,885 )

Less: total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

     —         (86 )     (587 )     (1,552 )
    


 


 


 


Pro forma net income (loss)

   $ (466,923 )   $ 1,748,478     $ (114,670 )   $ (142,437 )
    


 


 


 


Basic and diluted net income (loss) per share:

                                

As reported

   $ (18.68 )   $ 63.86     $ (4.17 )   $ (5.14 )

Pro forma

   $ (18.68 )   $ 63.85     $ (4.19 )   $ (5.20 )

 

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following range of assumptions used for the option grants which last occurred during fiscal 2002:

 

     2002

 

Volatility

   119.8 %

Risk-free interest rate

   4.6%-4.9 %

Expected life in years

   5.0  

Dividend yield

   0.0 %

 

Upon emergence from bankruptcy, all outstanding employee stock options were cancelled. The Company approved the 2004 Stock Incentive Plan, however, awards under this plan are subject to shareholder approval. For further discussion of the Company’s stock option plans, see Note 16.

 

F-17


Table of Contents

EXIDE TECHNOLOGIES AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

This excerpt taken from the XIDE 10-K filed Mar 1, 2005.

Stock Options

 

As provided for in SFAS No. 123, “Accounting for Stock-Based Compensation” (“SFAS 123”) the Company utilizes the intrinsic value method of expense recognition under APB Opinion No. 25. Accordingly, no

 

F-12


Table of Contents

EXIDE TECHNOLOGIES AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

compensation cost has been recognized for the stock option plans. Had compensation expense for the stock option plans been determined consistently with the provisions of SFAS 123, the Company’s net income (loss) and net income (loss) per share would have been the pro forma amounts indicated below:

 

     Fiscal Year Ended March 31,

 
     2004

    2003

    2002

 

Net loss as reported:

   $ (114,083 )   $ (140,885 )   $ (304,082 )

Less: total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

     (587 )     (1,552 )     (1,769 )
    


 


 


Pro forma net loss

   $ (114,670 )   $ (142,437 )   $ (305,851 )
    


 


 


Basic and diluted net loss per share:

                        

As reported

   $ (4.17 )   $ (5.14 )   $ (11.35 )

Pro forma

   $ (4.19 )   $ (5.20 )   $ (11.41 )

 

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following range of assumptions used for the option grants which last occurred during fiscal 2002:

 

     2002

 

Volatility

   119.8 %

Risk-free interest rate

   4.6%-4.9 %

Expected life in years

   5.0  

Dividend yield

   0.0 %

 

For a discussion of the Company’s options as a result of emergence from Chapter 11, see Note 29.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki